T1	p 44 67	inclusion body myositis
T2	p 216 326	44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks .
T3	i 75 115	treatment with methotrexate or placebo .
T4	i 159 176	oral methotrexate
T5	i 286 304	placebo-controlled
T6	i 525 537	methotrexate
T7	i 553 560	placebo
T8	i 840 852	methotrexate
T9	i 878 895	oral methotrexate
T10	o 20 40	weakness progression
T11	o 193 212	disease progression
T12	o 327 389	Mean change of quantitative muscle strength testing sum scores
T13	o 430 477	Quantitative muscle strength testing sum scores
T14	o 660 747	manual muscle testing sum scores , activity scale scores and patients ' own assessments
T15	o 778 808	Serum creatine kinase activity
T16	o 914 944	progression of muscle weakness
T17	o 959 991	serum creatine kinase activity .